Alabama Attorney General Fights to Stop Mail-Order Abortions

Alabama Attorney General Steve Marshall has issued cease-and-desist letters to six companies found to be illegally advertising, facilitating and enabling the sale and procurement of chemical abortion-inducing drugs to people in Alabama.

The sales of dangerous abortion pills violate the state’s pro-life law that protect babies from abortions.

“Alabama’s law is clear, abortion is illegal in this state. These companies are not only breaking the law, they are deceiving Alabama consumers about the very real dangers of these drugs. That stops now. Anyone who tries to exploit Alabamians for profit while flouting our laws will be prosecuted to the fullest extent permitted by law,” Attorney General Marshall said.

Each cease-and-desist letter demands that the recipient company halt all advertising, sale and delivery of abortion-inducing drugs to consumers in Alabama.

LifeNews is on TruthSocial. Please follow us here.

Failure or refusal to comply will trigger a formal investigation and possible legal action for unlawful trade practices, which can include civil penalties up to $2,000 per violation under Alabama’s consumer protection statutes.

Under Alabama law, the use, prescription or administration of any “medicine, drug, or any other substance or device with the intent to terminate the pregnancy of a woman known to be pregnant” is illegal. It is thus unlawful for out-of-state companies to send abortifacients by mail to individuals in Alabama.

The letters also raise concerns that the companies are misleading consumers in Alabama about the safety of the drugs.

Each company assures women that abortion pills are “safe,” even though medical evidence directly contradicts the claim.

For instance, a 2025 analysis of an all-payer insurance claims database identified that of 865,727 women prescribed mifepristone, 10.93 percent of women experienced serious adverse symptoms including sepsis, infection, hemorrhaging and other life-threatening complications.

The action comes amid heightened national scrutiny of mail-order abortion pills.

The FDA has launched a safety study of mifepristone, the primary drug used in chemical abortions. The review, expected to take about six months, is examining risks associated with the drug, particularly when distributed remotely without in-person medical oversight.

A recent analysis of commercial insurance claims involving 865,727 mifepristone prescriptions from 2017 to 2023. It found 94,605 women — nearly 11% — suffered serious complications within 45 days, including hemorrhage in 3.31% of cases, emergency room visits in 4.73%, and sepsis in 0.10%.

Peer-reviewed research found three quarters of ER visits within 30 days after abortion drug use were coded as severe or critical. Two separate, independent studies also found more than 1 in 10 women experience at least one severe adverse event. Complications can include hemorrhaging, infection, sepsis, and even death.

Other issues encompassed infections, transfusions, hospitalizations and life-threatening events like cardiac problems or anaphylaxis. In nearly 3% of cases, the drug failed, requiring surgical follow-up. Multiple women have died from the abortion pill.

A large national poll found 7 in 10 voters want to roll back Biden’s mail-order abortion drug rule and reinstate safeguards like in-person doctor visits.